Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1989 Sep;86(17):6778–6782. doi: 10.1073/pnas.86.17.6778

Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors.

W H Daughaday 1, M Kapadia 1
PMCID: PMC297929  PMID: 2771956

Abstract

We reported that serum and tumor from a hypoglycemic patient with a fibrosarcoma contained insulin-like growth factor II (IGF-II), mostly in a large molecular form designated "big IGF-II." We now describe two additional patients with non-islet-cell tumor with hypoglycemia (NICTH) whose sera contained big IGF-II. Removal of the tumor eliminated most of the big IGF-II from the sera of two patients. Because specific IGF-binding proteins modify the bioactivity of IGFs, the sizes of the endogenous IGF-binding protein complexes were determined after neutral gel filtration through Saphadex G-200. Normally about 75% of IGFs are carried as a ternary complex of 150 kDa consisting of IGF, a growth hormone (GH)-dependent IGF-binding protein, and an acid-labile complexing component. The three patients with NICTH completely lacked the 150-kDa complex. IGF-II was present as a 60-kDa complex with variable contributions of smaller complexes. In the immediate postoperative period, a 110-kDa complex appeared rather than the expected 150-kDa complex. Abnormal IGF-II binding may be important in NICTH because the 150-kDa complexes cross the capillary membrane poorly. The smaller complexes present in our patients' sera would be expected to enter interstitial fluid readily, and a 4- to 5-fold increase in the fraction of IGFs reaching the target cells would result.

Full text

PDF
6778

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AUGUST J. T., HIATT H. H. Severe hypoglycemia secondary to a nonpancreatic fibrosarcoma with insulin activity. N Engl J Med. 1958 Jan 2;258(1):17–20. doi: 10.1056/NEJM195801022580104. [DOI] [PubMed] [Google Scholar]
  2. Baxter R. C. Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex. J Clin Endocrinol Metab. 1988 Aug;67(2):265–272. doi: 10.1210/jcem-67-2-265. [DOI] [PubMed] [Google Scholar]
  3. Baxter R. C., Martin J. L. Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma. J Clin Invest. 1986 Dec;78(6):1504–1512. doi: 10.1172/JCI112742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Binoux M., Hossenlopp P. Insulin-like growth factor (IGF) and IGF-binding proteins: comparison of human serum and lymph. J Clin Endocrinol Metab. 1988 Sep;67(3):509–514. doi: 10.1210/jcem-67-3-509. [DOI] [PubMed] [Google Scholar]
  5. Daughaday W. H., Emanuele M. A., Brooks M. H., Barbato A. L., Kapadia M., Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988 Dec 1;319(22):1434–1440. doi: 10.1056/NEJM198812013192202. [DOI] [PubMed] [Google Scholar]
  6. Daughaday W. H., Mariz I. K., Blethen S. L. Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. J Clin Endocrinol Metab. 1980 Oct;51(4):781–788. doi: 10.1210/jcem-51-4-781. [DOI] [PubMed] [Google Scholar]
  7. Daughaday W. H., Trivedi B., Kapadia M. Measurement of insulin-like growth factor II by a specific radioreceptor assay in serum of normal individuals, patients with abnormal growth hormone secretion, and patients with tumor-associated hypoglycemia. J Clin Endocrinol Metab. 1981 Aug;53(2):289–294. doi: 10.1210/jcem-53-2-289. [DOI] [PubMed] [Google Scholar]
  8. Goldberg A. C., Trivedi B., Delmez J. A., Harter H. R., Daughaday W. H. Uremia reduces serum insulin-like growth factor I, increases insulin-like growth factor II, and modifies their serum protein binding. J Clin Endocrinol Metab. 1982 Dec;55(6):1040–1045. doi: 10.1210/jcem-55-6-1040. [DOI] [PubMed] [Google Scholar]
  9. Hardouin S., Hossenlopp P., Segovia B., Seurin D., Portolan G., Lassarre C., Binoux M. Heterogeneity of insulin-like growth factor binding proteins and relationships between structure and affinity. 1. Circulating forms in man. Eur J Biochem. 1987 Dec 30;170(1-2):121–132. doi: 10.1111/j.1432-1033.1987.tb13676.x. [DOI] [PubMed] [Google Scholar]
  10. Haselbacher G. K., Irminger J. C., Zapf J., Ziegler W. H., Humbel R. E. Insulin-like growth factor II in human adrenal pheochromocytomas and Wilms tumors: expression at the mRNA and protein level. Proc Natl Acad Sci U S A. 1987 Feb;84(4):1104–1106. doi: 10.1073/pnas.84.4.1104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Höppener J. W., Mosselman S., Roholl P. J., Lambrechts C., Slebos R. J., de Pagter-Holthuizen P., Lips C. J., Jansz H. S., Sussenbach J. S. Expression of insulin-like growth factor-I and -II genes in human smooth muscle tumours. EMBO J. 1988 May;7(5):1379–1385. doi: 10.1002/j.1460-2075.1988.tb02954.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. MILLER D. R., BOLINGER R. E., JANIGAN D., CROCKETT J. E., FRIESEN S. R. Hypoglycemia due to nonpancreatic mesodermal tumors: report of two cases. Ann Surg. 1959 Oct;150:684–696. doi: 10.1097/00000658-195910000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Martin J. L., Baxter R. C. Insulin-like growth factor-binding protein from human plasma. Purification and characterization. J Biol Chem. 1986 Jul 5;261(19):8754–8760. [PubMed] [Google Scholar]
  14. Megyesi K., Kahn C. R., Roth J., Gorden P. Circulating NSILA-s in man: Preliminary studies of stimuli in vivo and of binding to plasma components. J Clin Endocrinol Metab. 1975 Sep;41(3):475–484. doi: 10.1210/jcem-41-3-475. [DOI] [PubMed] [Google Scholar]
  15. Megyesi K., Kahn C. R., Roth J., Gorden P. Hypoglycemia in association with extrapancreatic tumors: demonstration of elevated plasma NSILA-s by a new radioreceptor assay. J Clin Endocrinol Metab. 1974 May;38(5):931–934. doi: 10.1210/jcem-38-5-931. [DOI] [PubMed] [Google Scholar]
  16. Póvoa G., Enberg G., Jörnvall H., Hall K. Isolation and characterization of a somatomedin-binding protein from mid-term human amniotic fluid. Eur J Biochem. 1984 Oct 15;144(2):199–204. doi: 10.1111/j.1432-1033.1984.tb08449.x. [DOI] [PubMed] [Google Scholar]
  17. Reeve A. E., Eccles M. R., Wilkins R. J., Bell G. I., Millow L. J. Expression of insulin-like growth factor-II transcripts in Wilms' tumour. Nature. 1985 Sep 19;317(6034):258–260. doi: 10.1038/317258a0. [DOI] [PubMed] [Google Scholar]
  18. Ron D., Powers A. C., Pandian M. R., Godine J. E., Axelrod L. Increased insulin-like growth factor II production and consequent suppression of growth hormone secretion: a dual mechanism for tumor-induced hypoglycemia. J Clin Endocrinol Metab. 1989 Apr;68(4):701–706. doi: 10.1210/jcem-68-4-701. [DOI] [PubMed] [Google Scholar]
  19. Scott J., Cowell J., Robertson M. E., Priestley L. M., Wadey R., Hopkins B., Pritchard J., Bell G. I., Rall L. B., Graham C. F. Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues. Nature. 1985 Sep 19;317(6034):260–262. doi: 10.1038/317260a0. [DOI] [PubMed] [Google Scholar]
  20. Scott M. G., Cuca G. C., Petersen J. R., Lyle L. R., Burleigh B. D., Daughaday W. H. Specific immunoradiometric assay of insulin-like growth factor I with use of monoclonal antibodies. Clin Chem. 1987 Nov;33(11):2019–2023. [PubMed] [Google Scholar]
  21. Tanaka H., Asami O., Hayano T., Sasaki I., Yoshitake Y., Nishikawa K. Identification of a family of insulin-like growth factor II secreted by cultured rat epithelial-like cell line 18,54-SF: application of a monoclonal antibody. Endocrinology. 1989 Feb;124(2):870–877. doi: 10.1210/endo-124-2-870. [DOI] [PubMed] [Google Scholar]
  22. Tricoli J. V., Rall L. B., Karakousis C. P., Herrera L., Petrelli N. J., Bell G. I., Shows T. B. Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res. 1986 Dec;46(12 Pt 1):6169–6173. [PubMed] [Google Scholar]
  23. Widmer U., Zapf J., Froesch E. R. Is extrapancreatic tumor hypoglycemia associated with elevated levels of insulin-like growth factor II? J Clin Endocrinol Metab. 1982 Nov;55(5):833–839. doi: 10.1210/jcem-55-5-833. [DOI] [PubMed] [Google Scholar]
  24. Yeoh S. I., Baxter R. C. Metabolic regulation of the growth hormone independent insulin-like growth factor binding protein in human plasma. Acta Endocrinol (Copenh) 1988 Dec;119(4):465–473. doi: 10.1530/acta.0.1190465. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES